论文部分内容阅读
目的:探讨Nogo-B在人脑胶质瘤组织中的表达和临床意义。方法:选取脑胶质瘤组织79例,另选取其他手术切除的正常脑组织标本30例。采用免疫组化技术法检测脑胶质瘤组织和正常脑组织中Nogo-B蛋白表达水平,并分析其与脑胶质瘤临床病理特征之间的关系。结果:正常脑组织与胶质瘤间Nogo-B阳性表达比较,差异有统计学意义,χ2=7.45,P<0.01。胶质瘤中Nogo-B的表达在患者肿瘤直径和WHO分级间差异有统计学意义,χ2值分别为7.93和8.42,P<0.01;而在患者性别、年龄、肿瘤部位间差异无统计学意义,P>0.05。结论:Nogo-B表达可能与脑胶质瘤的恶性程度有关,可以作为一个治疗胶质瘤的新靶点。
Objective: To investigate the expression of Nogo-B in human glioma and its clinical significance. Methods: Totally 79 glioma tissues were selected. Thirty other normal brain tissues were selected for resection. Immunohistochemistry was used to detect the expression of Nogo-B protein in glioma tissue and normal brain tissue, and to analyze its relationship with the clinicopathological features of glioma. Results: The positive expression of Nogo-B in normal brain tissue and glioma was significantly different (χ2 = 7.45, P <0.01). The expression of Nogo-B in gliomas was significantly different between the tumor diameter and the WHO classification (χ2 = 7.93 and 8.42, respectively, P <0.01). There was no significant difference in the gender, age and tumor location between the two groups , P> 0.05. Conclusion: The expression of Nogo-B may be related to the malignant degree of glioma and may serve as a new target for the treatment of glioma.